| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan [S. H., Y. F., M. L., T. Kato, T. W., T. Kata., Y. N.], Department of Gastroenterological Surgery, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan [S. H., S. S., T. Kato, T. W., Y. Y.]; and Laboratory for Medical Informatics, SNP Research Center, Riken (Institute of Physical and Chemical Research), Tokyo, Japan [T. T.]
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Histological studies have classified gastric carcinomas into two distinct groups, namely the intestinal (or differentiated) type and the diffuse (or undifferentiated) type (2) , having different features with regard to epidemiology, etiology, pathogenesis, and biological behavior. The intestinal type occurs more commonly in elderly people and has better prognosis, but diffuse-type gastric cancer is seen in relatively younger individuals, without preference for either sex, and displays a more invasive phenotype with a serious clinical course. Intestinal-type gastric cancer is presumed to result from atrophic gastritis, followed by progression to intestinal metaplasia and/or dysplasia (3) , but the precursor lesion of the diffuse-type tumor is not known.
Epidemiological and experimental studies have revealed that a high intake of smoked, salted, and nitrated foods and a low intake of vegetables and fruits increase the risk of gastric cancer and also that Helicobacter pylori infection is a risk factor for the disease (4) . Molecular investigations have provided evidence that multiple genetic alterations are involved in gastric tumorigenesis. Loss of heterozygosity (LOH) is observed frequently at loci on chromosomes 1p, 5q, 7p, 12q, 13q, 17p, 18q, and Y (5) . Genetic alterations and/or amplification of oncogenes including KRAS2 (c-K-ras), CTNNB1 (ß-catenin), ERBB2 (c-erbB-2), FGFR2 (K-sam), CCNE1 (cyclin E), and HGFR (c-MET) play roles in some gastric cancers, and inactivation of tumor suppressor genes such as p53, RB, APC, DCC, and/or CDH1 (E-cadherin) is often a factor as well (6) . In fact, germ-line mutation in CDH1 is responsible for disease in a subset of patients with familial gastric cancer, who usually suffer from diffuse-type tumors (7) . On the other hand, mutations in APC or CTNNB1 are observed preferentially in intestinal-type tumors. Although genetic changes in the genes just mentioned have been intensively studied, altered expression of larger numbers of genes in gastric cancer tissues remains to be disclosed.
A critical factor affecting the prognosis of most solid tumors in humans is lymph node metastasis, an independent risk factor for recurrence of gastric cancer. A few genes are already known to be associated with this process; for example, amplification of c-erbB-2 (8) , enhanced expression of VEGF-c (9) , or reduced expression of nm23 or E-cadherin (10 , 11) correlate with metastasis to lymph nodes. However, the molecular mechanisms involved remain unclear.
In this article, we report a genome-wide analysis of gene-expression profiles of intestinal-type gastric cancer tissues obtained by laser-capture microdissection; RNAs from the tumor cells were hybridized to a cDNA microarray containing 23,040 genes. In this manner, we identified a large set of genes with altered expression in intestinal-type cancers as well as a small number associated with lymph node metastasis.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Laser-Capture Microdissection, Extraction of RNA, and T7-based RNA Amplification.
Cancer cells and noncancerous gastric epithelium (
2 x 104 cells from each sample) were selectively collected from the preserved samples using laser-capture microdissection (12)
. Extraction of total RNA and T7-based amplification were performed as described previously (12)
. Aliquots (2.5-µg) of aRNA3
from each cancerous and noncancerous tissue were labeled with Cy3-dCTP and Cy5-dCTP, respectively.
cDNA Microarray and Analysis of Data.
Fabrication of the cDNA microarray slides, hybridization, washing, and detection of signals were carried out as described previously (12)
. The fluorescence intensities of Cy5 (nontumor) and Cy3 (tumor) for each target spot were adjusted so that the mean Cy3:Cy5 ratios of 52 housekeeping genes were equal to one. Because data derived from low signal intensities are less reliable, we first determined cutoff values for signal intensities on each slide so that all of the filtered genes had greater S:N (signal to noise) ratios of Cy3 or Cy5 than three, and we excluded genes for further analysis when both Cy3 and Cy5 dyes gave signal intensities lower than the cutoff. To estimate the range of expression ratio within which the expression change could be considered as fluctuation in noncancerous cells, we compared expression profiles of noncancerous epithelial cells from five patients. Because 90% of expression ratios in noncancerous cells fell within the range of 1.73 and 0.50, we categorized genes into three groups according to their expression ratios (Cy3:Cy5): up-regulated (ratio,
2.0); down-regulated (ratio
0.5); and unchanged expression (ratios, between 0.5 and 2.0). Genes with Cy3:Cy5 ratios >2.0 or <0.5 in more than 75% of the cases examined were defined as commonly up- or down-regulated genes, respectively. The significance of altered expression of each gene was also evaluated by calculating the Ps using a random permutation test as described previously (12)
. A permutation P of <0.01 was considered to be significant.
Quantitative RT-PCR.
We selected three commonly up-regulated genes (SOX9, NME1, PLAB) and a gene with altered expression between node-positive and node-negative tumors (NEDD8) and examined their expression levels by applying the real-time PCR technique (TaqMan PCR; Applied Biosystems, Foster City, CA). The glutaminyl-tRNA synthetase (QARS) gene served as an internal control because it showed the smallest Cy3:Cy5 fluctuation in our experiments. The TaqMan assay was carried out with the same aRNAs used for array analysis, and those from 11 additional samples that were not used for array analysis, according to the manufacturers protocol. The PCR process was started at 95°C for 10 min, then underwent 40 cycles at 95°C for 15 s and 60°C for 1 min. The sequences of primers and probes were as follows: QARS forward primer, 5'-GGTGGATGCAGCATTAGTGGA-3' and reverse, 5'-AAGACGCTCAAACTGGAACTTGTC-3'; probe, 5'-VIC-CTCTGTGGCCCTGGCAAAACCCTT-TAMRA-3'; NME1 forward primer, 5'-CAGAGAAGGAGATCGGCTTGTG-3' and reverse, 5'-CTTGTCATTCATAGATCCAGTT-3'; probe, 5'-FAM-CACCCTGAGGAACTGGTAGATTACACGAGC-TAMRA-3'; PLAB forward primer, 5'-GTGCTCATTCAAAAGACCGACA-3' and reverse, 5'-GGAAGGACCAGGACTGCTCATAT-3'; probe, 5'-FAM-TTAGCCAAAGACTGCCAC-TAMRA-3'; SOX9 forward primer, 5'-TGCAAGCATGTGTCATCCA-3' and reverse, 5'-AGCAATCCTCAAACTCTCTAGCC-3'; probe, 5'-FAM-CTCTGCATCTTCTCTTGGAGTG-TAMRA-3'; and NEDD8 forward primer, 5'-AGGTGGTCTTAGGCAGTGATGG-3' and reverse, 5'-TGGCTATGGTGTCCCAGAGAGT-3'; probe, 5'-FAM-CTTTACCCTGTCGCTCATAATGAGGCATCA-TAMRA-3'.
Identification of Differentially Regulated Genes and Development of Prediction Scores.
A random permutation test was carried out to identify "predictor" genes that showed significant differences in mean expression level (Cy3:Cy5) between node-positive and node-negative tumors, as reported previously (13)
. A permutation P of <0.01 was considered to be significant. To select a set of genes by which two classes were best discriminated, we used discriminant analysis (14
, 15)
. In forward stepwise discriminant analysis, a model of discrimination was built step-by-step. At each step, all of the expression ratios (Cy3:Cy5) were reviewed and evaluated to determine which one would contribute most to the discrimination of the two classes. The candidate genes were included in the prediction model, and the process was repeated until any inclusion did not contribute to the improvement of the prediction model. The analysis determined a discriminant coefficient (kj) of each predictor gene (j) and a constant value (C = -1.945). We calculated the "predictive score (
)" of each sample (i) by the following formula:
![]() |
| RESULTS |
|---|
|
|
|---|
|
|
Among the commonly down-regulated genes were some that are specific to gastric mucosa and involved in lipid metabolism (MTP, APOB, and APOA4), carbohydrate metabolism (KHK, ADH3, ALDH3, FBP1, ADH1, ALDOB, and MGAM), drug metabolism (CYP2C9, CYP3A7, and CYP3A5), carbon dioxide metabolism (LOC56287 and CA2), defense response (TFF1 and TFF2), or transport of small molecules or heavy metals (ATP2A3, GIF, ATP4B, and MT1E).
On examining the reliability of data obtained from our microarray analysis, we found that reproducibility was >85% when we excluded genes with signal intensities lower than the cutoff values. To verify the microarray data more quantitatively, we selected three commonly up-regulated genes (NME1, SOX9, and PLAB) and a gene the expression level of which was significantly altered between the node-positive and -negative tumors (NEDD8) and performed quantitative RT-PCR using 18 pairs of aRNA samples used for array analysis and nine additional pairs that were not used for the array analysis. Both results were very similar to the microarray data for all four genes (Fig. 1)
, supporting the reliability and rationality of our strategy.
|
|
|
| DISCUSSION |
|---|
|
|
|---|
The work reported here disclosed commonalities among intestinal-type gastric cancers through the analysis of expression of more than 20,000 genes. Genes that were commonly altered in the tumors that we examined represented widely diverse functions. Several that had been cited by others for association with gastric carcinogenesis, such as ERBB2, EGFR, and CCNE, were not included in our list because the frequency of their up-regulation in our experiments did not fit our defined criterion for commonly up-regulated genes (i.e., frequency of 75% or more). For instance, ERBB2, EGFR, and CCNE were reported to be overexpressed in 20, 50, and 20% of intestinal gastric cancers, respectively (18) , and in our study, those genes showed expression ratios of >2) in only 45, 62.5, and 10% of the tumors, respectively.
Some of the up-regulated genes had been already reported to be involved in carcinogenesis or cell proliferation. Those included genes associated with signal transduction: HGF, which is known to be the ligand of receptor-type tyrosine kinase; and c-MET, which was reported to be up-regulated in various cancers including gastric cancers (19 , 20) . Overexpression of HGF and MET genes might activate the HGF/MET signaling pathway in an autocrine manner and play a crucial role in gastric carcinogenesis. Altered expression of transcription factors including NFIL3, LHX1, and HOXB7 was reported in leukemia (21, 22, 23, 24) and solid tumors (23) . In addition, the list of up-regulated genes includes genes related to intracellular metabolism, DNA replication, and protein synthesis and processing, a result that might reflect accelerated growth and/or cell division. Interestingly, genes related to blood coagulation [PROCR (25) , SERPING1, and HRG (26) ] were also up-regulated in cancer cells as well. Because coagulopathy is a common complication among cancer patients, the administration of drugs inhibiting these targets may help to relieve patients with gastric cancer from coagulation defects.
On the other hand, 63 genes, including 22 functionally unknown genes, were down-regulated in more than 75% of the gastric carcinomas we examined. This list includes genes involved in the metabolism of carbohydrates, lipids, and drugs, or in the transport of small molecules. Several genes having specific functions in gastric epithelium were down-regulated as well; many of those encode products associated with absorption of nutrients or barriers against bacteria in the intestinal lumen. Hence down-regulation of these genes may reflect "de-differentiation" during carcinogenesis.
Metastasis to lymph nodes is one of the most useful prognostic factors for cancer patients. Recently two groups demonstrated that VEGF-C and -D play critical roles in this process (27 , 28) . However, the complex mechanisms of metastasis cannot be fully explained by alterations in just a few genes. Therefore our identification of a set of genes that were differently expressed between node-positive and node-negative tumors should contribute to an improved understanding of the precise biophysical events. For example, among the 12 genes that showed significantly different expression levels between the two groups, DDOST and GNS are known to be involved in the metabolism of glycoproteins that are constituents of extracellular matrix and cell-surface adhesion molecules. Therefore DDOST and/or GNS may mediate a process that modifies proteins associated with cell-adhesion or invasion. In addition, AIM2 (absent in melanoma), a putative tumor suppressor gene, was down-regulated in our node-positive group compared with node-negative tumors. Further analysis of these genes may clarify their roles in metastasis.
Predictive scores based on expression levels of the five genes described here as "discriminators" should have an impact on clinical practice because these scores could separate node-positive tumors from node-negative tumors with a high probability without the need to remove lymph nodes for examination. Although verification using a larger number of cases is essential, this predictive model may become a powerful tool for clinical purposes. Moreover, our results indicate that genome-wide analysis of gene expression analysis using laser-capture microdissection techniques and cDNA microarrays can provide useful information for clarifying the mechanism of development and progression of gastric cancers and for identifying new therapeutic targets and biomarkers for this disease.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
1 This work was supported in part by Research for the Future Program Grant 00L01402 from the Japan Society for the Promotion of Science. ![]()
2 To whom requests for reprints should be addressed, at Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan. ![]()
3 The abbreviations used are: aRNA, amplified RNA; RT-PCR, reverse transcription-PCR; VEGF, vascular endothelial growth factor. ![]()
Received 2/ 8/02. Accepted 10/ 4/02.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y. Shimizu, L. Meunier, and L. M. Hendershot pERp1 is significantly up-regulated during plasma cell differentiation and contributes to the oxidative folding of immunoglobulin PNAS, October 6, 2009; 106(40): 17013 - 17018. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Capoccia, W. J. Huh, and J. C. Mills How form follows functional genomics: gene expression profiling gastric epithelial cells with a particular discourse on the parietal cell Physiol Genomics, April 10, 2009; 37(2): 67 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Imai, S. Hirata, A. Irie, S. Senju, Y. Ikuta, K. Yokomine, M. Harao, M. Inoue, T. Tsunoda, S. Nakatsuru, et al. Identification of a Novel Tumor-Associated Antigen, Cadherin 3/P-Cadherin, as a Possible Target for Immunotherapy of Pancreatic, Gastric, and Colorectal Cancers Clin. Cancer Res., October 15, 2008; 14(20): 6487 - 6495. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Tsai, R. Herrera-Goepfert, R. J. Tibshirani, S. Yang, A. Mohar, J. Guarner, and J. Parsonnet Changes of Gene Expression in Gastric Preneoplasia following Helicobacter pylori Eradication Therapy. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 272 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Kim, H.-Y. Sohn, S. Y. Yoon, J.-H. Oh, J. O. Yang, J. H. Kim, K. S. Song, S.-M. Rho, H. S. Yoo, Y. S. Kim, et al. Identification of Gastric Cancer-Related Genes Using a cDNA Microarray Containing Novel Expressed Sequence Tags Expressed in Gastric Cancer Cells Clin. Cancer Res., January 15, 2005; 11(2): 473 - 482. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Uchida, T. Tsunoda, S. Wada, Y. Furukawa, Y. Nakamura, and H. Tahara Ring Finger Protein 43 as a New Target for Cancer Immunotherapy Clin. Cancer Res., December 15, 2004; 10(24): 8577 - 8586. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakatsura, H. Komori, T. Kubo, Y. Yoshitake, S. Senju, T. Katagiri, Y. Furukawa, M. Ogawa, Y. Nakamura, and Y. Nishimura Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell-Mediated Tumor Rejection without Autoimmune Reactions in Mice Clin. Cancer Res., December 15, 2004; 10(24): 8630 - 8640. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mocellin, E. Wang, M. Panelli, P. Pilati, and F. M. Marincola DNA Array-Based Gene Profiling in Tumor Immunology Clin. Cancer Res., July 15, 2004; 10(14): 4597 - 4606. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tamoto, M. Tada, K. Murakawa, M. Takada, G. Shindo, K.-i. Teramoto, A. Matsunaga, K. Komuro, M. Kanai, A. Kawakami, et al. Gene-Expression Profile Changes Correlated with Tumor Progression and Lymph Node Metastasis in Esophageal Cancer Clin. Cancer Res., June 1, 2004; 10(11): 3629 - 3638. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Mintzer, M. Warhol, A.-M. Martin, and G. Greene Cancer of Unknown Primary: Changing Approaches. A Multidisciplinary Case Presentation from the Joan Karnell Cancer Center of Pennsylvania Hospital Oncologist, June 1, 2004; 9(3): 330 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Oue, Y. Hamai, Y. Mitani, S. Matsumura, Y. Oshimo, P. P. Aung, K. Kuraoka, H. Nakayama, and W. Yasui Gene Expression Profile of Gastric Carcinoma: Identification of Genes and Tags Potentially Involved in Invasion, Metastasis, and Carcinogenesis by Serial Analysis of Gene Expression Cancer Res., April 1, 2004; 64(7): 2397 - 2405. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Dahlberg, L. F. Ferrin, S. M. Grindle, C. M. Nelson, C. D. Hoang, and B. Jacobson Gene expression profiles in esophageal adenocarcinoma Ann. Thorac. Surg., March 1, 2004; 77(3): 1008 - 1015. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Meireles, E. B. Cristo, A. F. Carvalho, R. Hirata Jr., A. Pelosof, L. I. Gomes, W. K. Martins, M. D. Begnami, C. Zitron, A. L. Montagnini, et al. Molecular Classifiers for Gastric Cancer and Nonmalignant Diseases of the Gastric Mucosa Cancer Res., February 15, 2004; 64(4): 1255 - 1265. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kim, S. Bang, S. Lee, S. Kim, Y. Jung, C. Lee, K. Choi, S.-G. Lee, K. Lee, Y. Lee, et al. Expression Profiling and Subtype-Specific Expression of Stomach Cancer Cancer Res., December 1, 2003; 63(23): 8248 - 8255. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Boussioutas, H. Li, J. Liu, P. Waring, S. Lade, A. J. Holloway, D. Taupin, K. Gorringe, I. Haviv, P. V. Desmond, et al. Distinctive Patterns of Gene Expression in Premalignant Gastric Mucosa and Gastric Cancer Cancer Res., May 15, 2003; 63(10): 2569 - 2577. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |